Jump to content
PC Security Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Mason Joe

Members
  • Content Count

    13
  • Joined

  • Last visited

Community Reputation

0 Neutral
  1. To order this detailed 300+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html Key Inclusions § A detailed assessment of the current market landscape, including information on drug developer(s), § A detailed assessment of the current market landscape of companies offering patient recruitment and retention services, including information on over 10 types of patient outreach methods employed, types of services offered ([A] patient recruitment (including pre-screening an
  2. A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed a significant burden on drug developer companies, prompting them to enlist the services of specialty service providers. Presently, close to 140 companies are actively offering patient recruitment and retention services. Majority of these players possess vast service portfolios and utilize diverse patient outreach methods to recruit study participants across different geographies and therapeutic indications. To order this 300+ page report, which features 90+ figure
  3. Roots Analysis has done a detailed study on Patient Recruitment and Retention Services Marker, 2019-2030.”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 300+ page report, which features 90+ figures and 140+ tables, please visit this -https://www.rootsanalysis.com/reports/view_document/patient-recruitment-and-retention-services-market-2019-2030/245.html Key Market Insights § Presently, close to 140 companies claim to be actively engaged in offering patient recruitment / retention services to
  4. A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers Roots Analysis is pleased to announce the publication of its recent study, titled, “Patient Recruitment and Retention Services Marker, 2019-2030.” The report offers a comprehensive study of the current scenario and future potential of the players providing patient enrollment and retention services. The study features an in-depth analysi
  5. To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html Key Inclusions § A detailed assessment of the current market landscape of endocannabinoid system targeted therapeutics, providing information on phase of development (clinical, preclinical, and discovery stage) of lead candidates, target therapeutic area (s), route of administration (oral, topical, sublingual, oromucosal, inhalation and others), dosing frequency (once daily, twice daily, thri
  6. Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids. To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannab
  7. Roots Analysis has done a detailed study on Endocannabinoid System Targeted Therapeutics Market, 2020-2030 “ covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html Key Market Insights § More than 65 industry players across the world are presently engaged in evaluating the clinical applications of over180 cannabinoid-derivatives that
  8. So far, more than 100 different cannabinoids have been identified, and there is a growing body of evidence supporting the clinical benefits of this class of compounds in treating the symptoms of a wide variety of chronic health conditions Roots Analysis is pleased to announce the publication of its recent study, titled, Endocannabinoid System Targeted Therapeutics Market, 2020-2030 The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of endocannabinoid system targeting drugs, over the next decade. Th
  9. So far, more than 100 different types of cannabinoids have been identified and there is a growing body of evidence supporting the benefits of this class of compounds in offering symptomatic relief for a wide variety of chronic health conditions London Roots Analysis has announced the addition of “Endocannabinoid System Targeted Therapeutics Market, 2020-2030” report to its list of offerings. Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients
  10. To order this detailed 350+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors/303.html Key Inclusions § A detailed assessment of the current market landscape, including information on drug developer(s), phase of development (marketed, clinical and preclinical / discovery stage) of lead candidates, target immune checkpoints, their respective mechanisms of action (inhibitory or stimulatory), type of therapeutic modality used (monoclonal antibody, antibody fragment, small molecule and others), route of administrati
  11. Over time, significant strides have been made in immune checkpoint research, resulting in the discovery of several inhibitory (LAG-3, TIM-3, TIGIT, VISTA and B7-H3) and stimulatory receptors (OX40, ICOS, GITR, 4-1BB and CD40), which are being investigated as potential targets for therapy development. Further, studies of combinatorial immune checkpoint blockade / co-stimulation, targeting newly identified checkpoints along with known checkpoint inhibitor therapies, have demonstrated promising clinical outcomes as well. To order this 350+ page report, which features 140+ figures and
  12. Roots Analysis has done a detailed study on Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030., covering key aspects of the industry’s evolution and identifying potential future growth opportunities. To order this 350+ page report, which features 140+ figures and 170+ tables, please visit this link Key Market Insights § More than 150 industry players across the world are presently engaged in evaluating the potential of nearly 300 next generation immune checkpoint modulators for the treatment of multiple disease indications § The
  13. Therapies targeting novel inhibitory and stimulatory immune checkpoints have been shown to possess substantial therapeutic potential, both as monotherapies and in combination with other interventions, across multiple disease interventions Roots Analysis is pleased to announce the publication of its recent study, titled, “Next Generation Immune Checkpoint Inhibitors and Stimulators Market, 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapies over the next decade. It feat
×
  • Create New...